Prime Medicine

PRME · NASDAQ

$3.92+$0.09 (+2.35%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $3.83

PRME analyst rating

BuyConsensus of 7 analysts over the last 12 months. 86% rate it a buy.

Strong buy0
Buy6
Hold1
Underperform0
Sell0

12-month price target · 13 analysts

Average $7.26 (+85.1% upside)

Low: $4.29
Now: $3.92
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

PRME analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	Sep 25, 2026	Maintains	Buy	$7.00	38%
Chardan Capital	Aug 25, 2026	Maintains	Buy	$7.00	38%
BMO Capital	Aug 19, 2026	Initiates	Outperform	$9.00	55%
HC Wainwright & Co.	Aug 10, 2026	Maintains	Buy	$8.00	47%
HC Wainwright & Co.	Jun 29, 2026	Upgrade	Neutral → Buy	$8.00	47%
Oppenheimer	Mar 12, 2026	Initiates	Outperform	$11.00	22%
LifeSci Capital	Dec 23, 2025	Initiates	Outperform	$6.00	—
Citigroup	Nov 11, 2025	Maintains	Neutral	$5.00 → $4.25	36%
Chardan Capital	Nov 10, 2025	Maintains	Buy	$10.00 → $9.00	43%

The case for and against

Updated Oct 14, 2026

Bull case

Prime Medicine is viewed positively because it has now cleared major regulatory hurdles for two liver-directed programs, PM577a and PM647, while validating its modular prime-editing platform through repeated use of the same LNP delivery system. The Wilson disease program targets the H1069Q ATP7B variant, which represents 30-50% of cases and has preclinical support for biomarker-driven proof of concept, while PM647 showed approximately 53% and 70% hepatocyte editing and restored M-AAT into or above the healthy human range. Its balance sheet and partnered economics also matter: $109 mm of cash funds two programs into 2027, Bristol Myers Squibb provided a $55 million upfront payment plus a $55 million equity investment, and PM359’s RMAT status strengthens the broader curative thesis.

Bear case

Prime Medicine is viewed negatively because its gene-editing pipeline still faces major clinical and regulatory uncertainty, including patient recruitment constraints, off-target editing risks, and no certainty of approval or reimbursement in the US or elsewhere. Its targeted markets in Wilson disease, Alpha-1 antitrypsin deficiency, and cystic fibrosis may prove smaller or more competitive than expected, while pricing and the need to build commercial infrastructure could pressure adoption. Financially, cash of $109 mm as of 30 June versus $191.4M at end-FY25 suggests a high burn profile and likely future capital raises, creating dilution risk and a runway into 2027 that remains an overhang.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.